In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Deciphera funds clinical work with $185.9mm public offering

Executive Summary

Oncology drug development company Deciphera Pharmaceuticals Inc. netted $185.9mm through its first public offering since its September 2017 IPO. The company sold 4.9mm common shares (including the overallotment) at $40, and intends to use the majority of the proceeds ($100mm) to fund continued development of lead candidate DCC2618, which is in Phase III trials as a fourth-line treatment for gastrointestinal stromal tumors (GIST) and earlier trials for additional advanced cancers.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies

Advertisement
UsernamePublicRestriction

Register